Welcome to the Podiatry Arena forums

You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members, upload content, view attachments, receive a weekly email update of new discussions, access other special features. Registered users do not get displayed the advertisements in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!

  1. Have you considered the Clinical Biomechanics Boot Camp Online, for taking it to the next level? See here for more.
    Dismiss Notice
Dismiss Notice
Have you considered the Clinical Biomechanics Boot Camp Online, for taking it to the next level? See here for more.
Dismiss Notice
Have you liked us on Facebook to get our updates? Please do. Click here for our Facebook page.
Dismiss Notice
Do you get the weekly newsletter that Podiatry Arena sends out to update everybody? If not, click here to organise this.

Dermagraft

Discussion in 'Diabetic Foot & Wound Management' started by Antonio, Jul 12, 2006.

  1. Antonio

    Antonio Welcome New Poster


    Members do not see these Ads. Sign Up.
    Why would the company that bought Dermagraft but Dermagraft if Apligraf is avaible? I do not understand the reason for Dermagraft?
     
  2. DaVinci

    DaVinci Well-Known Member

    Not quite sure what you are asking????
     
  3. Admin2

    Admin2 Administrator Staff Member

  4. Craig Payne

    Craig Payne Moderator

    Articles:
    8
    Apligraf is
    and is manufactured by Organogenesis Inc

    Dermagraft is
    and used to be made by Smith & Nephew until they sold it to Advanced BioHealing.

    Both products have similar indications, but are essentially competitors.
     
  5. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Autologous full-thickness skin substitute for healing chronic wounds
    British Journal of Dermatology Volume 155 Page 267 - August 2006
     
  6. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Update on Tissue-Engineered Biological Dressings.
    Tissue Eng. 2006 Jul 1;
     
  7. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Experience with the use of apligraf to heal complicated surgical and nonsurgical wounds in a private practice setting.
    Adv Skin Wound Care. 2006 Jul-Aug;19(6):310-23
     
  8. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Apligraf

    Evaluation of Apligraf(R) persistence and basement membrane restoration in donor site wounds: a pilot study.
    Hu S, Kirsner RS, Falanga V, Phillips T, Eaglstein WH.
    Wound Repair Regen. 2006 Jul-Aug;14(4):427-33.
     
  9. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Efficacy and Safety of Fresh Fibroblast Allografts in the Treatment of Diabetic Foot Ulcers.
    Dermatol Surg. 2009 Jun 3. [Epub ahead of print]
     
  10. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Human Fibroblast-Derived Dermal Substitute: Results from a Treatment Investigational Device Exemption (TIDE) Study in Diabetic Foot Ulcers.
    Warriner RA 3rd, Cardinal M; on behalf of the TIDE Investigators.
    Adv Skin Wound Care. 2011 Jul;24(7):306-311.
     
  11. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Press Release:
    Health Economics Model Shows That Dermagraft® Combined With Conventional Care is a Cost-Effective Treatment for Diabetic Foot Ulcers in Medicare and Commercially Insured Populations
    June 24, 2011
     
  12. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Press Release:
    Top-Line Results from Pivotal Trial of Dermagraft® for Venous Leg Ulcers
     
  13. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Press Release:
    DERMAGRAFT® Approved in Canada for Treatment of Diabetic Foot Ulcers

     
  14. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Press Release:
    Organogenesis Inc. Announces Acquisition of Dermagraft® from Shire
    Product Acquisition Solidifies Organogenesis Position as Industry Leader
     
  15. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Treatment of Postoperative Lower Extremity Wounds Using Human Fibroblast-Derived Dermis: A Retrospective Analysis.
    Carlson RM, Smith NC, Dux K, Stuck RM.
    Foot Ankle Spec. 2014 Feb 11.
     
  16. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    The Incidence of Lower-Extremity Amputation and Bone Resection in Diabetic Foot Ulcer Patients Treated with a Human Fibroblast-Derived Dermal Substitute.
    Frykberg RG, Marston WA, Cardinal M.
    Adv Skin Wound Care. 2014 Nov 18
     
  17. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    The Incidence of Lower-Extremity Amputation and Bone Resection in Diabetic Foot Ulcer Patients Treated with a Human Fibroblast-Derived Dermal Substitute.
    Frykberg RG, Marston WA, Cardinal M.
    Adv Skin Wound Care. 2015 Jan;28(1):17-20.
     
  18. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Press release:
    MiMedx Announces Receipt Of Civil Subpoena
     
  19. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
  20. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Press Release:
    Organogenesis Secures $30 Million in Financing to Fund Aggressive Expansion of Commercial Operations and Product Portfolio
    Apr 14, 2016, 11:50 ET from Organogenesis Inc.
     
  21. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    After rocky 2 years, Organogenesis is regenerating business
     
  22. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    DOJ Reach $350M Deal In Dermagraft FCA Investigation
     
Loading...

Share This Page